To uncover cancer cell-intrinsic or tumor microenvironment (TME) mechanisms conferring resistance to endocrine and CDK4/6 inhibition therapies in earlier-stage patient tumors, detailed molecular interrogation of serial biopsies across patient cohorts is needed (Hanker et al, 2020; Watt and Goel, 2022). Here, CDK4 is linked to neoplasm.